tetano
Editor, Senior Moderator
Med Drug Discov. 2020 Mar;5:100026. doi: 10.1016/j.medidd.2020.100026. Epub 2020 Mar 25.
Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
Ji H[SUP]1[/SUP], Yan Y[SUP]1[/SUP], Ding B[SUP]1[/SUP], Guo W[SUP]1[/SUP], Brunswick M[SUP]1[/SUP], Niethammer A[SUP]1[/SUP], SooHoo W[SUP]1[/SUP], Smith R[SUP]1,[/SUP][SUP]2[/SUP], Nahama A[SUP]1[/SUP], Zhang Y[SUP]1[/SUP].
Author information
Abstract
A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called "I-cells". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for "off-the-shelf" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.
? 2020 The Authors.
KEYWORDS:
Antigen; COVID-19; Coronavirus; SARS-CoV-2; Transgenic cell vaccination; Vaccine
PMID:32289117PMCID:PMC7144842DOI:10.1016/j.medidd.2020.100026
Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus.
Ji H[SUP]1[/SUP], Yan Y[SUP]1[/SUP], Ding B[SUP]1[/SUP], Guo W[SUP]1[/SUP], Brunswick M[SUP]1[/SUP], Niethammer A[SUP]1[/SUP], SooHoo W[SUP]1[/SUP], Smith R[SUP]1,[/SUP][SUP]2[/SUP], Nahama A[SUP]1[/SUP], Zhang Y[SUP]1[/SUP].
Author information
Abstract
A novel approach modifying cells to express viral markers to elicit protective immunity responses (decoy cellular vaccination) in the prevention of COVID-19 disease is currently being explored. Our approach entails utilizing SARS-CoV-2 Spike antigen-expressing, non-replicating cells as carriers and presenters of immunogenic antigens, so called "I-cells". By using irradiated cells as presenting vehicles of SARS-CoV-2 viral antigens(s) in a cellular context, these presented viral proteins can be recognized by the host immune system, thus, an efficient protective immune response might be elicited. Another advantage of this strategy is that the manufacturing process is scalable and yields uniform cell products allowing for "off-the-shelf" frozen supply availability. To prevent engraftment and proliferation of the cells after administration, the cells will be irradiated post-harvesting abolishing in vivo replication potential. Specifically, immunoreactive Spike-1 proteins from SARS-CoV-2 are expressed on the surface of irradiated target I-cells. Utilizing this innovative strategy, these viral antigen-displaying decoy cells will be developed as a vaccine to protect against COVID-19 disease.
? 2020 The Authors.
KEYWORDS:
Antigen; COVID-19; Coronavirus; SARS-CoV-2; Transgenic cell vaccination; Vaccine
PMID:32289117PMCID:PMC7144842DOI:10.1016/j.medidd.2020.100026